ICD-10 Coding for Elevated Carcinoembryonic Antigen(R97.0, R97.0B, R97.0E)
Learn about the ICD-10 coding for elevated carcinoembryonic antigen (CEA), including documentation requirements, coding pitfalls, and clinical validation.
Complete code families applicable to Elevated Carcinoembryonic Antigen
Key Information
Essential facts and insights aboutElevated Carcinoembryonic Antigen
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Elevated Carcinoembryonic Antigen.
Documenting 'elevated tumor markers' without specificity
Impact
Clinical: Lack of specificity can lead to misinterpretation., Regulatory: Non-compliance with documentation standards., Financial: Potential claim denials due to insufficient documentation.
Mitigation
Always specify the type of tumor marker., Include exact values and clinical context.
Using R97.0 as primary code for active cancer
Impact
Reimbursement: Incorrect sequencing can lead to claim denials., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate clinical data representation.
Mitigation
Sequence the malignancy code first, followed by R97.0.
Use of R97.0 without documented neoplasm
Impact
Coding R97.0 without a documented history of neoplasm can trigger audits.
Mitigation
Ensure documentation includes history or suspicion of malignancy.